利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

679 条记录 (耗时 0.043 秒)

    Pharmaceutical compound
    6.
    发明授权
    Pharmaceutical compound 有权

    公开(公告)号：US11130738B2

    公开(公告)日：2021-09-28

    申请号：US16780349

    申请日：2020-02-03

    申请人： IOmet Pharma Ltd.

    发明人： Phillip M. Cowley ,  Alan Wise ,  Susan Davis ,  Michael Kiczun

    IPC分类号： A61K31/416 ,  A61K31/435 ,  A61K31/438 ,  A61K31/439 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/551 ,  A61K31/5377 ,  C07D231/56 ,  C07D401/04 ,  C07D403/04 ,  C07D471/08 ,  C07D471/10 ,  C07D417/12 ,  C07D498/08 ,  C07D498/04 ,  C07D487/04 ,  C07D471/04 ,  C07D498/10 ,  C07D405/06 ,  C07D401/14 ,  C07D261/20 ,  C07D403/14 ,  C07D403/12 ,  C07D417/14 ,  A61K45/06

    摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises formula (I) wherein X1, and X2 may be the same or different and each is independently selected from C, N, O and S; X3, X4, X5, and X6 may be the same or different and each is independently selected from C and N; each bond represented by a dotted line may be present or absent, provided that at least one such bond is present; R1, R2, R3, R4, R5 and R6 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R1, R2, R3, R4, R5 and R6 groups present is such that the respective valencies of X1, X2, X3, X4, X5, and X6 are maintained; and wherein at least one of R5 and R6 comprises a group Y, wherein Y is a group having a formula selected from (II), (III), (IV), (V), (VI), (VII) wherein L may be present or absent, and may be a substituted or unsubstituted organic linking group; R31 and R32 may be the same or different and are selected from H and a substituted or unsubstituted organic group; each R34 may be the same or different and is selected from H and a substituted or unsubstituted organic group; R35 is selected from a substituted or unsubstituted alcohol group or ether group; each R36 may be the same or different and is selected from H and a substituted or unsubstituted organic group; X7 may be selected from C and N; X8, X9, X10, X11, X12, X13, X14, X15 and X16 may be the same or different and each is independently selected from C, N, O and S; each bond represented by a dotted line may be present or absent; and each R313 may be the same or different and is selected from H and a substituted or unsubstituted organic group.

    COMBINATION THERAPY FOR THE TREATMENT OF PANCREATIC CANCER
    7.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT OF PANCREATIC CANCER 有权

    公开(公告)号：US20210283120A1

    公开(公告)日：2021-09-16

    申请号：US17180522

    申请日：2021-02-19

    申请人： Genentech, Inc.

    发明人： Jeff Settleman ,  Nisebita Sahu

    IPC分类号： A61K31/4523 ,  A61K31/519 ,  A61K31/166 ,  A61K31/18 ,  A61K31/4184 ,  A61K31/44 ,  A61K45/06 ,  A61K31/5025 ,  A61K31/437 ,  A61P35/00

    摘要： The subject matter described herein is directed to compositions comprising a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor that targets PDGFRα, S6 and STAT3 or a pharmaceutically acceptable salt thereof, and their use in treating pancreatic cancer. In another aspect, disclosed herein are methods of treating pancreatic cancer by administering a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor, or a pharmaceutically acceptable salt thereof. In another aspect, the combination of cobimetinib, or a pharmaceutically acceptable salt thereof, and ponatinib or a pharmaceutically acceptable salt thereof is administered in a composition or the combination is administered separately to treat pancreatic cancer.